Drug Ophthalmology

Tryptyr

Payments companies reported to CMS as associated with Tryptyr. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$2.6Massociated payments (2023-2025)

7,502clinicians with associated payments

2companies reporting

By year

2025 $2.6M

Payments reported as associated with Tryptyr, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Ophthalmology $1.3M

Optometrist $1.1M

Ophthalmic Plastic and Reconstructive Surgery $64K

Cornea and External Diseases Specialist $30K

Corneal and Contact Management $25K

Glaucoma Specialist $20K

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Tryptyr

These are the largest totals companies reported as associated with Tryptyr. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

Clinician	Location	Specialty	Associated payments (2023-2025)
Beeran Meghpara	Philadelphia, PA	Ophthalmology	$73,707.23
Nathan Lighthizer	Tahlequah, OK	Optometrist	$69,337.86
Sheri Rowen	Newport Beach, CA	Ophthalmology	$66,994.22
Laura Periman	Seattle, WA	Ophthalmology	$66,661.99
Marjan Farid	Irvine, CA	Ophthalmic Plastic and Reconstructive Surgery	$63,194.11
Mark Milner	Palm Beach Gardens, FL	Ophthalmology	$62,118.82
Eric Rosenberg	New York, NY	Ophthalmology	$55,545.87
Cory Lappin	Montgomery, OH	Optometrist	$51,449.09
Preeya Gupta	Raleigh, NC	Ophthalmology	$51,343.77
Lisa Nijm	Springfield, IL	Ophthalmology	$48,845.76

Prescribed Tryptyr?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

What this means, and what it doesn't

These payments are legal and common. Drug and device makers routinely pay for meals at educational events, consulting, speaking, travel, and research. Companies are required by federal law to report them; that's why this data exists.
A payment is not evidence of wrongdoing. Most clinicians who accept industry payments provide excellent care. Research payments in particular often reflect participation in clinical trials.
Context beats raw numbers. A few hundred dollars in sandwiches over several years is typical. What's worth understanding is scale, source, and purpose, which is what this page shows.
The data comes from companies, not doctors. Figures are "as reported to CMS" by the paying companies. Clinicians can dispute records through CMS's official process.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.